186 related articles for article (PubMed ID: 34450472)
1. Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients' experiences in Australia.
Barnett A; Savic M; Lintzeris N; Bathish R; Arunogiri S; Dunlop AJ; Haber P; Graham R; Hayes V; Lubman DI
Drug Alcohol Depend; 2021 Oct; 227():108959. PubMed ID: 34450472
[TBL] [Abstract][Full Text] [Related]
2. The dynamics of more-than-human care in depot buprenorphine treatment: A new materialist analysis of Australian patients' experiences.
Barnett A; Pienaar K; Lubman DI; Arunogiri S; Phan V; Hayes V; Lintzeris N; Savic M
Int J Drug Policy; 2024 May; 127():104399. PubMed ID: 38636315
[TBL] [Abstract][Full Text] [Related]
3. Long-acting injectable depot buprenorphine from a harm reduction perspective in patients with ongoing substance use and multiple psychiatric comorbidities: a qualitative interview study.
Johnson B; Monwell B; Capusan AJ
Harm Reduct J; 2024 Mar; 21(1):68. PubMed ID: 38528531
[TBL] [Abstract][Full Text] [Related]
4. Exploring patient experience and satisfaction with depot buprenorphine formulations: A mixed-methods study.
Allen E; Samadian S; Altobelli G; Johnson J; Holmwood C
Drug Alcohol Rev; 2023 May; 42(4):791-802. PubMed ID: 36788357
[TBL] [Abstract][Full Text] [Related]
5. Depot buprenorphine injections for opioid use disorder: Patient information needs and preferences.
Neale J; Tompkins CNE; Strang J
Drug Alcohol Rev; 2019 Jul; 38(5):510-518. PubMed ID: 31131514
[TBL] [Abstract][Full Text] [Related]
6. Treatment of opioid dependence with depot buprenorphine (CAM2038) in custodial settings.
Dunlop AJ; White B; Roberts J; Cretikos M; Attalla D; Ling R; Searles A; Mackson J; Doyle MF; McEntyre E; Attia J; Oldmeadow C; Howard MV; Murrell T; Haber PS; Lintzeris N
Addiction; 2022 Feb; 117(2):382-391. PubMed ID: 34184798
[TBL] [Abstract][Full Text] [Related]
7. Prolonged-release opioid agonist therapy: qualitative study exploring patients' views of 1-week, 1-month, and 6-month buprenorphine formulations.
Neale J; Tompkins CNE; Strang J
Harm Reduct J; 2019 Apr; 16(1):25. PubMed ID: 30943990
[TBL] [Abstract][Full Text] [Related]
8. Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial.
Lintzeris N; Dunlop AJ; Haber PS; Lubman DI; Graham R; Hutchinson S; Arunogiri S; Hayes V; Hjelmström P; Svedberg A; Peterson S; Tiberg F
JAMA Netw Open; 2021 May; 4(5):e219041. PubMed ID: 33970256
[TBL] [Abstract][Full Text] [Related]
9. Opioid users' willingness to receive prolonged-release buprenorphine depot injections for opioid use disorder.
Tompkins CNE; Neale J; Strang J
J Subst Abuse Treat; 2019 Sep; 104():64-71. PubMed ID: 31370986
[TBL] [Abstract][Full Text] [Related]
10. Can a new formulation of opiate agonist treatment alter stigma?: Place, time and things in the experience of extended-release buprenorphine depot.
Treloar C; Lancaster K; Gendera S; Rhodes T; Shahbazi J; Byrne M; Degenhardt L; Farrell M
Int J Drug Policy; 2022 Sep; 107():103788. PubMed ID: 35816790
[TBL] [Abstract][Full Text] [Related]
11. Depot buprenorphine as an opioid agonist therapy in New South Wales correctional centres: a costing model.
Ling R; White B; Roberts J; Cretikos M; Howard MV; Haber PS; Lintzeris N; Reeves P; Dunlop AJ; Searles A
BMC Health Serv Res; 2022 Nov; 22(1):1326. PubMed ID: 36348369
[TBL] [Abstract][Full Text] [Related]
12. 'I just thought that was the best thing for me to do at this point': Exploring patient experiences with depot buprenorphine and their motivations to discontinue.
Clay S; Treloar C; Degenhardt L; Grebely J; Christmass M; Gough C; Hayllar J; McDonough M; Henderson C; Crawford S; Farrell M; Marshall A
Int J Drug Policy; 2023 May; 115():104002. PubMed ID: 37003194
[TBL] [Abstract][Full Text] [Related]
13. Economic analysis of out-of-pocket costs among people in opioid agonist treatment: A cross-sectional survey in three Australian jurisdictions.
Tran AD; Chen R; Nielsen S; Zahra E; Degenhardt L; Santo T; Farrell M; Larance B
Int J Drug Policy; 2022 Jan; 99():103472. PubMed ID: 34649203
[TBL] [Abstract][Full Text] [Related]
14. Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone.
Rolland B; Trojak B; Nourredine M; Bachellier J; Chappuy M; Bendimerad P; Kosim M; Hjelmström P; Meroueh F; Nubukpo P; Brousse G
Drug Alcohol Depend; 2021 Mar; 220():108492. PubMed ID: 33482572
[TBL] [Abstract][Full Text] [Related]
15. Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: protocol for the CoLAB study.
Larance B; Byrne M; Lintzeris N; Nielsen S; Grebely J; Degenhardt L; Shahbazi J; Shanahan M; Lancaster K; Dore G; Ali R; Farrell M;
BMJ Open; 2020 Jul; 10(7):e034389. PubMed ID: 32737087
[TBL] [Abstract][Full Text] [Related]
16. Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia.
Larance B; Degenhardt L; Grebely J; Nielsen S; Bruno R; Dietze P; Lancaster K; Larney S; Santo T; Shanahan M; Memedovic S; Ali R; Farrell M
Addiction; 2020 Jul; 115(7):1295-1305. PubMed ID: 31860767
[TBL] [Abstract][Full Text] [Related]
17. Administration and patient-incurred costs associated with opioid agonist treatment in Norway.
Pedersen MH; Danø A; Gibbons C; Jensen R
Curr Med Res Opin; 2022 Nov; 38(11):1959-1965. PubMed ID: 36172758
[TBL] [Abstract][Full Text] [Related]
18. Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis.
Yarborough BJ; Stumbo SP; McCarty D; Mertens J; Weisner C; Green CA
Drug Alcohol Depend; 2016 Mar; 160():112-8. PubMed ID: 26796596
[TBL] [Abstract][Full Text] [Related]
19. Does the advent of depot therapy represent a step change in our understanding of opioid use disorder and its treatment?
Roberts E; Humphreys K
Drug Alcohol Rev; 2024 Jan; 43(1):261-264. PubMed ID: 37525510
[TBL] [Abstract][Full Text] [Related]
20. Global opioid agonist treatment: a review of clinical practices by country.
Jin H; Marshall BDL; Degenhardt L; Strang J; Hickman M; Fiellin DA; Ali R; Bruneau J; Larney S
Addiction; 2020 Dec; 115(12):2243-2254. PubMed ID: 32289189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
